Target of tisotumab vedotin-tftv

Tisotumab vedotin-tftv is an antibody-drug conjugate containing a tissue factor-specific fully human monoclonal antibody (TF-011) conjugated to monomethyl auristatin E (MMAE), which has been designed to target tissue factor-expressing tumors. Based on results from a Phase II trial, Vitin-Tisotuzumab has received accelerated approval in the United States for the treatment of adult patients with recurrent or metastatic cervical cancer whose disease has progressed during or after chemotherapy.

Approval was based on the innovaTV 204 trial, which evaluated efficacy in 101 patients with recurrent or metastatic cervical cancer who had received no more than two prior systemic regimens, including at least one prior platinum-based chemotherapy regimen. 69% of patients had received bevacizumab as part of previous systemic therapy. Patients received 2 mg/kg of vitin-tisotumab every 3 weeks until disease progression or unacceptable toxicity. The primary efficacy outcome measure was confirmed objective response rate (ORR) as assessed by an independent review committee (IRC) using RECIST v1.1 and duration of response (DOR), with an ORR of 24% and a median duration of response of 8.3 months.

Vitin-TisotumabThe original drug has not yet been marketed in China, so it cannot be included in medical insurance. The original drugs marketed overseas are very expensive. The price of each box of 40 mg/vial may be around RMB 90,000 (the price may fluctuate due to the exchange rate). Currently, there is no generic version of Vitin-Tisotuzumab on the market. For more drug information and specific prices, please consult the medical consultant of the drug.